Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Amble vs NowPatient

Amble
Graded #220

Level

vs
NowPatient
Graded #222

Level

The verdict

Too close to call — both grade 65.5/100 (C).

Amble and NowPatient land on the same WeighScore, so neither clears the other on our six graded dimensions. Amble sits one line higher on the board (#220 vs #222) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAmble +25
60
35
Dose & formulationNowPatient +29
64
93
Clinical oversightNowPatient +7
79
86
Labs & monitoringNowPatient +2
52
54
FulfillmentAmble +11
81
70
Contract termsEven
55
55
Amble · left barNowPatient · right bar

The numbers

MetricAmbleNowPatient
WeighScore65.5/10065.5/100
GradeCC
Scorecard rank#220#222
Semaglutide$179/mo (starting dose, compounded)$1,349/mo (brand Wegovy)
Tirzepatide$289/mo (starting dose, compounded)$1,069/mo (brand Mounjaro, promotional rate)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
Amble

Graded #220 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details
NowPatient

Graded #222 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard